Skip to main content
. Author manuscript; available in PMC: 2022 May 14.
Published in final edited form as: Circ Res. 2021 May 13;128(10):1451–1467. doi: 10.1161/CIRCRESAHA.121.318159

Figure 2. Mediations, associations and predictions involving inflammation markers in HFpEF.

Figure 2

Mediations (Green) between comorbidity burden, inflammatory biomarkers and echocardiographic cardiac function (TNFR1: Tumor Necrosis Factor Receptor 1; GDF15: Growth Differentiation Factor 15; IL1R1: Interleukin 1 Receptor 1; E: Early diastolic mitral flow velocity; E/e’: ratio of Early diastolic mitral flow velocity over Early diastolic long axis lengthening velocity; TR: Tricuspid Regurgitation velocity). Associations (Red) between inflammatory biomarkers and presence of HFpEF (CRP: C-Reactive Protein; IL6: Interleukin 6; IL1RL1: Interleukin 1 Receptor Like 1; Int Sub β 2: Integrin Subunit Beta 2). Biomarkers predicting (Orange) myocardial function or HFpEF (ICAM1: Intercellular Adhesion Molecule 1; TNFα: Tumor Necrosis Factor α; VCAM: Vascular Cell Adhesion Molecule; LVGLS: Left Ventricular Global Longitudinal Strain). Numbers indicate corresponding reference.